Liquid Biopsy Market By Analytes (Circulating Tumor Cells (CTCs), Circulating Tumor Dna (CtDNA), Extracellular Vesicles (EVs)), By Application (Prognosis, Diagnosis, Therapy Monitoring) - Market Growth, Future Prospects and Competitive Analysis, 2016 - 2022

Biomarker based diagnostics have already offered great advanced in the past decade in the field of cancer diagnosis, prognosis, staging and therapy selection. However, tissue-based detection approach produces a major drawback in terms of invasion for sample collection. Over the last few years, several cancer biomarker research studies have moved their focus on analysis of biomarkers found in biological fluids, which offer minimal invasion and longer disease tracking - liquid biopsy. Several cancer diagnostic companies and startups have accepted the challenge of commercializing liquid biopsy tools in the market.

For the purpose of this study, the liquid biopsy market is studied by analytes and applications. Based on analytes, this report studies circulating tumor cells (CTCs) circulating tumor DNA (ctDNA) and extracellular vesicles (SVs) segments. Liquid biopsy techniques find application in cancer prognosis, diagnosis and therapy monitoring. This report provides market size and forecast (USD Mn) for such considered segments for the period 2014-2022, along with their respective CAGRs (value %) for the period 2016-2022, considering 2015 as the base year.

Geographically, the global liquid biopsy market is categorized into the following regional markets:

North America

a.    U.S.

b.    Canada

Europe

a.    U.K.

b.    Germany

c.    Rest of Europe

Asia-Pacific

a.    Japan

b.    China

c.    Rest of Asia-Pacific

Middle East and Africa
Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 for the mentioned segments are also presented in this study.

This study also provides qualitative assessment tools for the readers that offer the overall status and trends in the liquid biopsy market. Such sections include market dynamics (drivers, challenges, future prospects), major commercial events, and major research events. For competitive assessment, tools such as attractive investment proposition and fractal map analysis (by key market players) are also presented in this study. This report concludes with company profiles section that highlights major information about key companies operating in the liquid biopsy market. Some of the major market players covered in this section include Myriad Genetics, Qiagen, Trovagene, Natera, Foundation Medicine, and others. The key information provided on these players is based on parameters such as business description, financial health, product portfolio, and news coverage.

The application areas studies for analyzing the liquid biopsy market are:

1.   Prognosis

2.   Diagnosis

3.   Therapy monitoring

4.   Others
 

Liquid biopsy has the potential to assist clinicians in determining cancer prognosis, stratification of patients to determine the best possible treatment modality and also assess resistance mechanisms of tumors. Molecular characterization of tumor is facilitated through liquid biopsy and its non-invasive nature paves way for repeated sampling to scrutinize genetic changes during any period, by avoiding tissue biopsy. 

Disease prognosis currently takes the highest share in the liquid biopsy applications market, whereas diagnostics and therapy monitoring closely compete with each other. Liquid biopsy can efficiently monitor the effectiveness of treatment regimen thus facilitate treatment optimization, and possible alterations. As the nature of tumors change over time, liquid biopsy offers the benefit of analyzing such dynamics and provide information for possible treatment change. In cases where particular genotypes are identified in patients, liquid biopsy allows early detection of cancer before the occurrence of overt symptoms.

Based on geographical segmentation, the global liquid biopsy market is studied for:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
• Latin America
• Middle East and Africa

North America is the current geographical leader in the liquid biopsy market. High demand for latest diagnostic modules, coupled with greater awareness between both patients and caregivers play a vital growth in the dominance of this region. Additionally, several giant market players and new startups operating in this market are domiciled in North America and Europe, thus allowing early bird advantage to these regions. 

Large number of research activities being conducted in the region also is a prime phenomenon in North America and Europe markets. However, challenged reimbursements may hold back the growth of this market to a certain extent. Introduction of cost effective solutions and rapid approvals in Latin America and Asia-Pacific will serve as the prime growth drivers in these regions